Key Segments:
By Phase
-
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design
-
- Interventional Studies
- Observational Studies
- Expanded Access Studies
By Indication
-
- Autoimmune/inflammation
- Pain management
- Oncology
- CNS conditions
- Diabetes
- Obesity
- Cardiovascular
- Others
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Hospitals & Clinics
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: Expensive omics technologies hamper the growth of the omics-based clinical trials market, thus limiting their wide adoption.
Ans: Omics-based clinical trials market companies are Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratories, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc. (Labcorp Drug Development), Novo Nordisk A/S, Rebus Biosystems, Thermo Fisher Scientific, Illumina, Agilent Technologies, Qiagen, Roche, Eurofins Scientific, Siemens Healthineers, Fulgent Genetics, NeoGenomics Laboratories, Tempus Labs, and other players.
Ans: Increasing demand for RNA-based therapeutics and vaccines is expected to drive the growth of the omics-based clinical trials market.
Ans: The Omics-based Clinical Trials Market was USD 32.75 billion in 2024 and is expected to reach USD 61.98 billion by 2032.
Ans: The Omics-based Clinical Trials Market is expected to grow at a CAGR of 8.36% from 2025 to 2032.